Merck, Ra enter into Cyclomimetics collaboration
This article was originally published in Scrip
Executive Summary
Merck & Co has entered into a collaboration with Ra Pharmaceuticals to develop a class of peptide-like molecules known as Cyclomimetics. The companies will study the compounds for a range of diseases.